Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

16.02.24		FDA approves Xolair as first and only medicine for children and adults with one or more food allergies (GlobeNewswire)
01.02.24		New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) (GlobeNewswire)
01.02.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline (GlobeNewswire)
01.02.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER) (GlobeNewswire)
16.01.24		European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types (GlobeNewswire)
29.12.23		Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform (GlobeNewswire)
19.12.23		FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results (GlobeNewswire)
15.12.23		Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices (GlobeNewswire)
11.12.23		New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma (GlobeNewswire)
09.12.23		New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A (GlobeNewswire)
08.12.23		Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treat (GlobeNewswire)
08.12.23		Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
05.12.23		Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
04.12.23		Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes (GlobeNewswire)
27.11.23		Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection (GlobeNewswire)
16.11.23		Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List (GlobeNewswire)
14.11.23		Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types (GlobeNewswire)
09.11.23		Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation (GlobeNewswire)
30.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functio (GlobeNewswire)
27.10.23		[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) (GlobeNewswire)
23.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory (GlobeNewswire)
19.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products (GlobeNewswire)
19.10.23		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum trotz Rückgang der Nachfrage nach COVID-19-Produkten (GlobeNewswire)
18.10.23		Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns (GlobeNewswire)
18.10.23		Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer (GlobeNewswire)
13.10.23		Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (GlobeNewswire)
12.10.23		New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided (GlobeNewswire)
11.10.23		Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions (GlobeNewswire)
10.10.23		Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies (GlobeNewswire)
04.10.23		Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment (GlobeNewswire)
02.10.23		Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD (GlobeNewswire)
07.09.23		Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardi (GlobeNewswire)
05.09.23		Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare (PR Newswire)
01.09.23		Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer (GlobeNewswire)
29.08.23		Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes (GlobeNewswire)
29.08.23		European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) (GlobeNewswire)
23.08.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
27.07.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products (GlobeNewswire)
27.07.23		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten (GlobeNewswire)
24.07.23		Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk (GlobeNewswire)
21.07.23		CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) (GlobeNewswire)
20.07.23		New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss (GlobeNewswire)
13.07.23		Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis (GlobeNewswire)
11.07.23		European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
30.06.23		Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk (GlobeNewswire)
16.06.23		FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
13.06.23		Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries (GlobeNewswire)
09.06.23		New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH) (GlobeNewswire)
17.05.23		Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis (GlobeNewswire)
09.05.23		FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) (GlobeNewswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Roche Peer Group Nachrichten

14:17		Bayer-Aktie gewinnt: Bayer veräußert große Teile seiner Kunstsammlung
12:27		Schwacher Handel: STOXX 50 zeigt sich am Mittag schwächer
12:27		Aufschläge in Europa: Euro STOXX 50 am Mittwochmittag mit Kursplus
12:27		LSE-Handel: FTSE 100 präsentiert sich fester
12:27		Börse Zürich in Rot: Das macht der SPI mittags
12:27		Zurückhaltung in Zürich: So bewegt sich der SLI am Mittag
12:27		XETRA-Handel LUS-DAX verbucht mittags Verluste
12:27		Pluszeichen in Frankfurt: DAX mit Gewinnen

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.02.2025 14:57
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten